618109-81-2

Basic information

• Product Name: methyl 3-amino-3-(4-tert-butylphenyl)propanoate
• Synonyms: methyl 3-amino-3-(4-tert-butylphenyl)propanoate
• CAS NO: 618109-81-2
• Molecular Formula: C14H21NO2
• Molecular Weight: 235.32204
• Mol File: 618109-81-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 3-amino-3-(4-tert-butylphenyl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-amino-3-(4-tert-butylphenyl)propanoate(618109-81-2)
• EPA Substance Registry System: methyl 3-amino-3-(4-tert-butylphenyl)propanoate(618109-81-2)

Safety Data

• Hazardous Substances Data: 618109-81-2(Hazardous Substances Data)

Upstream product

• 1746-23-2 4-tert-Butylstyrene 
• 67-56-1 methanol 
• 282524-82-7 (RS)-3-amino-3-(4-tert-butylphenyl)propionic acid 
• 939-97-9 4-tert-Butylbenzaldehyde 

Relevant articles and documents

Palladium-Catalyzed Intermolecular Azidocarbonylation of Alkenes via a Cooperative Strategy

A novel intermolecular β-azidocarbonylation reaction of alkenes has been developed in which a combination of iodine(III)-mediated alkene activation and palladium-catalyzed carbonylation was demonstrated as an efficient strategy for the difunctionalization of alkenes. A variety of β-azido carboxylic esters were obtained from mono- and 1,1-disubstituted terminal alkenes with excellent regioselectivities. In addition, the introduced azido group can be reduced to an amine group, providing a facile access to β-amino acid derivatives from simple olefins.

Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1)

All-trans-retinoic acid (ATRA), the biologically active metabolite of vitamin A, is used medicinally for the treatment of hyperproliferative diseases and cancers. However, it is easily metabolized. In this study, the leading compound S8 was found based on virtual screening. To improve the activity of the leading compound S8, a series of novel S8 derivatives were designed, synthesized and evaluated for their in vitro biological activities. All of the prepared compounds showed that substituting the 5-chloro-3-methyl-1-phenyl-1H-pyrazole group for the 2-tertbutyl-5-methylfuran scaffold led to a clear increase in the biological activity. The most promising compound 32, with a CYP26A1 IC50 value of 1.36 μM (compared to liarozole (IC50 = 2.45 μM) and S8 (IC50 = 3.21 μM)) displayed strong inhibitory and differentiation activity against HL60 cells. In addition, the study focused on the effect of β-phenylalanine, which forms the coordination bond with the heme of CYP26A1. These studies suggest that the compound 32 can be used as an appropriate candidate for future development.